Karyopharm Therapeutics (NASDAQ:KPTI) Posts Earnings Results, Misses Expectations By $0.95 EPS

Karyopharm Therapeutics (NASDAQ:KPTI) posted its earnings results on Thursday. The company reported ($2.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.37) by ($0.95), FiscalAI reports. The firm had revenue of $33.43 million during the quarter, compared to analysts’ expectations of $32.19 million.

Here are the key takeaways from Karyopharm Therapeutics’ conference call:

• Myelofibrosis sNDA remains on track for August 2026 under the FDA’s Accelerated Approval pathway, supported by rapid, deep, and sustained spleen-volume responses in the SENTRY trial and constructive FDA discussions.
• If approved, selinexor plus ruxolitinib could become the first approved combination therapy for myelofibrosis, with a potential launch as early as the first quarter of 2027 and estimated U.S. peak annual revenue of approximately $1 billion.
• Liquidity remains a significant risk: Karyopharm had $65.4 million in cash and investments at quarter-end, expects funding only into September 2026, and faces a $16.8 million term-loan payment on September 10 that could trigger a covenant breach without new financing, a waiver, or a strategic transaction.
• The company is reducing investment in endometrial cancer after the XPORT-EC-042 Phase III trial failed to reach statistical significance, while focusing resources on myelofibrosis and multiple myeloma; XPOVIO U.S. revenue nevertheless rose to $30.8 million from $29.7 million year over year.

Karyopharm Therapeutics Trading Down 2.0%

Shares of KPTI stock opened at $1.99 on Friday. Karyopharm Therapeutics has a 12 month low of $1.80 and a 12 month high of $10.99. The stock has a market cap of $45.10 million, a PE ratio of -0.13 and a beta of 0.89. The company’s fifty day moving average price is $7.61 and its 200-day moving average price is $7.90.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the business. Baird Financial Group Inc. purchased a new stake in Karyopharm Therapeutics in the second quarter worth about $45,000. XTX Topco Ltd purchased a new stake in shares of Karyopharm Therapeutics in the second quarter worth $56,000. Corient Private Wealth LLC bought a new position in shares of Karyopharm Therapeutics during the fourth quarter valued at $74,000. Tudor Investment Corp ET AL bought a new position in shares of Karyopharm Therapeutics during the fourth quarter valued at $95,000. Finally, Persistent Asset Partners Ltd purchased a new position in shares of Karyopharm Therapeutics in the 4th quarter worth about $135,000. 66.44% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

KPTI has been the subject of several research reports. Weiss Ratings lowered shares of Karyopharm Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, July 28th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Karyopharm Therapeutics in a research note on Tuesday, June 9th. Piper Sandler reduced their price target on shares of Karyopharm Therapeutics to $7.00 and set an “overweight” rating on the stock in a research report on Friday, July 31st. Robert W. Baird downgraded shares of Karyopharm Therapeutics from an “outperform” rating to a “neutral” rating and set a $3.00 price target for the company. in a research note on Friday, July 31st. Finally, HC Wainwright cut Karyopharm Therapeutics from a “buy” rating to a “negative” rating in a research report on Friday, July 31st. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Karyopharm Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $11.50.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics (NASDAQ: KPTI) is a clinical-stage biopharmaceutical company focused on discovering and developing novel first-in-class drugs that target the nuclear export protein XPO1. The company’s lead product, selinexor (marketed as XPOVIO), is an oral selective inhibitor of nuclear export (SINE) compound approved for treatment of multiple myeloma and diffuse large B-cell lymphoma. In addition to selinexor, Karyopharm’s pipeline includes second-generation SINE compounds and combination studies in solid tumors and hematologic malignancies.

Founded in 2008 and headquartered in Newton, Massachusetts, Karyopharm has built a research platform around modulation of nuclear export pathways.